This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.
Cagrilintide
Long-acting amylin analog investigated for obesity/weight management (incl. combinations such as CagriSema). Not a supplement.
Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.
Reuters news report (February 2026) described CagriSema outperforming semaglutide in a late-stage diabetes trial; this is now confirmed by the peer-reviewed REDEFINE 2 NEJM paper (see above).
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly) produced an estimated mean body-weight reduction of -20.4% vs -3.0% with placebo at week 68 (P<0.001), superior to either component alone. GI adverse events were common (majority transient & mild-to-moderate). Published in NEJM 2025.
CagriSema produced mean weight loss of -13.7% vs -3.4% with placebo at week 68, & 73.5% of patients achieved HbA1c ≤6.5% vs 15.9% with placebo. GI adverse events in 72.5% of CagriSema group (mostly transient/mild-moderate). Published in NEJM 2025.
Stacks containing Cagrilintide
Public community stacks that include this ingredient.
Clinical Weight Loss Protocol
Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).
Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).